Q4 2024 Dexcom Inc Earnings Call Transcript
Key Points
- DexCom Inc (DXCM) reported an 8% organic revenue growth in Q4 2024, aligning with their guidance.
- The company expanded its global customer base by 25% in 2024, reaching over 2.8 million users.
- DexCom Inc (DXCM) achieved significant coverage expansion, with two of the three largest PBMs now covering CGM for all diabetes patients.
- The launch of the over-the-counter product, Stelo, saw strong demand with over 140,000 users in the first four months.
- International revenue grew by 17% in Q4 2024, driven by new access wins and expanded product availability.
- US revenue growth was impacted by rebate eligibility, negatively affecting growth by several points in Q4.
- Gross profit margin decreased to 59.4% from 64.2% in Q4 2023, partly due to a $21 million noncash charge.
- Operating income decreased to 18.8% of revenue in Q4 2024 from 23.5% in the same quarter of 2023.
- The company is managing channel inventory tightly due to disruptions, expecting normalization by the end of Q1 2025.
- DexCom Inc (DXCM) faces challenges in expanding coverage for the remaining 20 million type 2 diabetes patients not on insulin in the US.
Thank you for standing by. My name is Abby, and I will be your conference operator today. At this time, I would like to welcome everyone to the Dexcom Inc. fourth-quarter 2024 earnings release conference call. (Operator Instructions)
I would now like to turn the call over to Sean Christensen, VP of Finance and Investor Relations. Please go ahead.
Thank you, Abby, and welcome to Dexcom's fourth quarter and fiscal year 2024 earnings call. Our agenda begins with Kevin Sayer, Dexcom's Chairman, President and CEO, who will summarize our recent highlights and ongoing strategic initiatives, followed by a financial review and outlook from Jereme Sylvain, our Chief Financial Officer.
Following our prepared remarks, we will open the call up for your questions. At that time, we ask analysts to limit themselves to one question each so we can provide an opportunity for everyone participating today. Please note that there are also slides available related to our fourth quarter
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
